Jeremy Paul Cetnar
Oregon Health & Science University · 98 works · 2,928 citations · h-index 20
Top works
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
- Immune Checkpoint Inhibitors in Organ Transplant Patients
- The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
- Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
- Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
- Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
- SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
- NLR is predictive of upstaging at the time of radical cystectomy for patients with urothelial carcinoma of the bladder
- Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours
- Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
- Effect of the American Society of Clinical Oncology’s Conflict of Interest Policy on Information Overload
- Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience.
- Immunotherapy in head and neck squamous cell carcinoma: An updated review
- Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
- Expression Microarray Meta-Analysis Identifies Genes Associated with Ras/MAPK and Related Pathways in Progression of Muscle-Invasive Bladder Transition Cell Carcinoma
- Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors
- Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer
- A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).
- Place of Residence and Primary Treatment of Prostate Cancer: Examining Trends in Rural and Nonrural Areas in Wisconsin